Molecular glue degrader for tumor treatment

Molecular glue degrader for tumor treatment

Targeted Protein Degradation (TPD) represented by Proteolysis-Targeting Chimeras (PROTAC) is the frontier field in the research and development of antitumor therapy, in which oral drug HP518 Receives FDA Proceed Authorization for its IND Application for Prostate Cancer Treatment. Recently, molecular...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuhan Hu, Yan Yan, Jiehao Wang, Jiangxue Hou, Quande Lin
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Oncology
Subjects:
molecular glue degrader
tumor
design strategies
mechanism
clinical trials
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1512666/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items